Skip to main content
S. 2495 117th Congress Senate

Protecting our Pharmaceutical Supply Chain from China Act of 2021

Official title: A bill to require the Secretary of Health and Human Services to maintain a list of the country of origin of all drugs marketed in the United States, to ban the… Show full official titleShow less

Official title: A bill to require the Secretary of Health and Human Services to maintain a list of the country of origin of all drugs marketed in the United States, to ban the use of Federal funds for the purchase of drugs manufactured in the People's Republic of China, and for other purposes.

Introduced: July 28, 2021 Introduced by: Tom Cotton Republican · Arkansas See on congress.gov
Health AsiaBusiness expensesChinaDrug safety, medical device, and laboratory regulation
More subjectsShow fewer subjects
Government information and archivesHealth care costs and insuranceHealth programs administration and fundingHealth technology, devices, suppliesIncome tax deductionsManufacturingMilitary medicineMilitary procurement, research, weapons developmentPrescription drugsPublic contracts and procurementTrade restrictionsVeterans' medical care
Sign in to write a letter Sign in to watch
This bill died when the 117th Congress ended
It never became law before the 117th Congress (2021–2022) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 28, 2021
Read twice and referred to the Committee on Finance.
Jul 28, 2021
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action July 28, 2021

Read twice and referred to the Committee on Finance.

 Plain-English summary Congressional Research Service

Protecting our Pharmaceutical Supply Chain from China Act of 2021

This bill requires the federal government to maintain a registry of certain foreign-sourced drugs, prohibits federal health care programs from purchasing drugs containing ingredients manufactured in China, requires drugs to be labeled for country of origin, and offers domestic manufacturing facility tax incentives.

The Food and Drug Administration shall maintain (1) a list of foreign-sourced drugs and active ingredients that are critical for consumer health and safety, and (2) another list identifying such drugs that are produced exclusively in China or use ingredients produced in China.

The bill phases in a restriction on federal health care programs purchasing drugs with active ingredients manufactured in China. By January 1, 2024, such programs may not purchase a drug with any active ingredients from China. The Department of Health and Human Services may issue a waiver for an agency or program that is unable to meet this requirement, but no waiver may apply to drugs purchased in or after 2026.

Each drug must have labeling listing the country of origin of each active ingredient, and a drug without this labeling shall be deemed misbranded.

The bill allows 100% tax expensing for qualified pharmaceutical and medical device manufacturing property placed in service between 2020 and 2026.

 Related & companion bills 2
  • S 3401 ABC Safe Drug Act
  • HR 7121 Protecting our Pharmaceutical Supply Chain from China Act of 2022
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 3
All 3 Republican 3
R
Blackburn, Marsha
Tennessee · Jul 28, 2021
 R
Cruz, Ted
Texas · Jul 28, 2021
 R
Scott, Rick
Florida · Jul 28, 2021
Cite this page click to expand
APA
U.S. Congress. (2026). S. 2495: Protecting our Pharmaceutical Supply Chain from China Act of 2021. 117th Congress. Open America. https://openamerica.io/bill/117-S-2495/
MLA
"S. 2495: Protecting our Pharmaceutical Supply Chain from China Act of 2021." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-S-2495/.
Bluebook (legal)
S. 2495, 117th Cong. (2026), https://openamerica.io/bill/117-S-2495/.
Markdown link
[S. 2495: Protecting our Pharmaceutical Supply Chain from China Act of 2021](https://openamerica.io/bill/117-S-2495/)
Report a problem